BB Biotech AG is a Swiss investment company in the field of biotechnology.

[8][18] Primary focus lies on small-to-mid-cap biotech companies headquartered in Western Europe[19] and especially the United States market.

[10][17][22] BB Biotech further concentrates on firms developing therapeutic products[7] involving cell, gene and particularly RNA-based technologies.

[8] It targets biotechnology firms which either have previously established products in the marketplace[23] or promising drug candidates in advanced development stages.

[24] While benchmarked against the Nasdaq Biotech index (in CHF),[25][26] the company uses a bottom-up approach[24] based on the fundamental analysis.